INTERVENTION 1:	Intervention	0
Stratum 1: Received Hormonal Therapy	Intervention	1
Participants received hormonal therapy	Intervention	2
INTERVENTION 2:	Intervention	3
Stratum 2: Had Not Received Hormonal Therapy	Intervention	4
Participants had not received hormonal therapy	Intervention	5
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Histologically or cytologically confirmed adenocarcinoma of the breast	Eligibility	1
adenocarcinoma	DOID:299	42-56
breast	UBERON:0000310	64-70
Stage III or IV disease	Eligibility	2
disease	DOID:4,OGMS:0000031	16-23
Primary or recurrent disease	Eligibility	3
recurrent	HP:0031796	11-20
disease	DOID:4,OGMS:0000031	21-28
Invasive lobular carcinoma allowed	Eligibility	4
invasive lobular carcinoma	DOID:3457	0-26
HLA-A1, -A2, -A3, or -A31 positive	Eligibility	5
Underwent and recovered from prior primary therapy	Eligibility	6
Patients with no clinical or radiological evidence of disease who had a previous diagnosis of stage III or IV breast cancer must have undergone prior antineoplastic therapy including, but not limited to, surgery, chemotherapy, and radiotherapy within the past 36 months	Eligibility	7
disease	DOID:4,OGMS:0000031	54-61
breast cancer	DOID:1612	110-123
surgery	OAE:0000067	204-211
radiotherapy	OAE:0000235	231-243
Must have at least one undissected axillary and/or inguinal lymph node basin	Eligibility	8
lymph	UBERON:0002391	60-65
No history of brain metastases	Eligibility	9
history	BFO:0000182	3-10
brain	UBERON:0000955	14-19
Hormone receptor status	Eligibility	10
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
Estrogen receptor-positive or -negative tumor	Eligibility	11
estrogen	CHEBI:50114,BAO:0000760	0-8
PATIENT CHARACTERISTICS:	Eligibility	12
patient	HADO:0000008,OAE:0001817	0-7
ECOG performance status of 0 or 1	Eligibility	13
Body weight > 110 lbs (without clothes)	Eligibility	14
body weight	CMO:0000012	0-11
Male or female	Eligibility	15
male	CHEBI:30780,PATO:0000384	0-4
male	CHEBI:30780,PATO:0000384	10-14
female	PATO:0000383	8-14
Menopausal status not specified	Eligibility	16
Absolute neutrophil count > 1000/mm^3	Eligibility	17
Platelet count > 100,000/mm^3	Eligibility	18
platelet count	CMO:0000029	0-14
Hemoglobin > 9 g/dL	Eligibility	19
hemoglobin	CHEBI:35143	0-10
Hemoglobin A1c < 7%	Eligibility	20
hemoglobin	CHEBI:35143	0-10
AST and ALT  2.5 x upper limit of normal (ULN)	Eligibility	21
x	LABO:0000148	17-18
Bilirubin  2.5 x ULN	Eligibility	22
x	LABO:0000148	15-16
Alkaline phosphatase  2.5 x ULN	Eligibility	23
phosphatase	GO:0016791,BAO:0000295	9-20
x	LABO:0000148	26-27
Creatinine  1.5 x ULN	Eligibility	24
creatinine	CHEBI:16737	0-10
x	LABO:0000148	16-17
HIV negative	Eligibility	25
Hepatitis C negative	Eligibility	26
hepatitis c	DOID:1883	0-11
Not pregnant or nursing	Eligibility	27
Negative pregnancy test	Eligibility	28
Fertile patients must use effective contraception	Eligibility	29
No known or suspected allergies to any component of the vaccine	Eligibility	30
vaccine	VO:0000001	56-63
No active infection requiring antibiotics	Eligibility	31
active	PATO:0002354	3-9
No New York Heart Association class III or IV heart disease	Eligibility	32
heart	UBERON:0000948	12-17
heart	UBERON:0000948	46-51
heart disease	DOID:114	46-59
No autoimmune disorders requiring cytotoxic or immunosuppressive therapy or autoimmune disorders with visceral involvement, except the following:	Eligibility	33
Laboratory evidence of autoimmune disease (e.g., positive ANA titer) without symptoms	Eligibility	34
autoimmune disease	DOID:417	23-41
Clinical evidence of vitiligo	Eligibility	35
vitiligo	HP:0001045,DOID:12306	21-29
Other forms of depigmenting illness	Eligibility	36
Mild arthritis requiring nonsteroidal antiinflammatory drugs	Eligibility	37
mild	HP:0012825	0-4
arthritis	HP:0001369,DOID:848	5-14
No medical contraindication or potential problem that would preclude study participation	Eligibility	38
contraindication	OAE:0000055	11-27
PRIOR CONCURRENT THERAPY:	Eligibility	39
More than 4 weeks since prior surgery	Eligibility	40
surgery	OAE:0000067	30-37
More than 4 weeks since prior and no concurrent chemotherapy and radiotherapy	Eligibility	41
radiotherapy	OAE:0000235	65-77
More than 4 weeks since prior and no concurrent allergy desensitization injections	Eligibility	42
allergy	HP:0012393	48-55
More than 4 weeks since prior parenteral, oral, or inhaled corticosteroids	Eligibility	43
No concurrent inhaled steroids (e.g., AdvairÂ® or triamcinolone acetonide)	Eligibility	44
triamcinolone acetonide	CHEBI:71418	49-72
Prior or concurrent topical corticosteroids allowed	Eligibility	45
More than 4 weeks since prior and no concurrent growth factors (e.g., epoetin alfa, darbepoetin alfa, or pegfilgrastim)	Eligibility	46
growth	GO:0040007	48-54
More than 4 weeks since prior and no concurrent other investigational medication	Eligibility	47
More than 4 weeks since prior and no concurrent other agents with putative immunomodulating activity except for non-steroidal anti-inflammatory agents	Eligibility	48
Prior and concurrent hormonal therapy (e.g., tamoxifen, raloxifene, toremifene, fulvestrant, letrozole, anastrozole, or exemestane) allowed	Eligibility	49
tamoxifen	CHEBI:41774	45-54
raloxifene	CHEBI:8772	56-66
toremifene	CHEBI:9635	68-78
fulvestrant	CHEBI:31638	80-91
letrozole	CHEBI:6413	93-102
anastrozole	CHEBI:2704	104-115
exemestane	CHEBI:4953	120-130
No prior vaccination with any synthetic peptides in this protocol	Eligibility	50
vaccination	VO:0000002	9-20
synthetic	BAO:0003073	30-39
Vaccines for infectious disease (e.g., influenza) allowed, provided they are administered  2 weeks prior to or  2 weeks after study vaccine	Eligibility	51
disease	DOID:4,OGMS:0000031	24-31
influenza	DOID:8469	39-48
vaccine	VO:0000001	0-7
vaccine	VO:0000001	132-139
Short term therapy for acute conditions not related to breast cancer allowed	Eligibility	52
acute	HP:0011009,PATO:0000389	23-28
breast cancer	DOID:1612	55-68
No concurrent illegal drugs	Eligibility	53
Outcome Measurement:	Results	0
The Number of Participants Who Experienced Dose-limiting Adverse Events	Results	1
Safety of the 9-peptide mixture if fewer than 33% of patients experience a dose-limiting toxicity	Results	2
mixture	CHEBI:60004	24-31
Time frame: 30 days post administration of last vaccine	Results	3
time	PATO:0000165	0-4
vaccine	VO:0000001	48-55
Results 1:	Results	4
Arm/Group Title: Stratum 1: Received Hormonal Therapy	Results	5
Arm/Group Description: Participants received hormonal therapy	Results	6
Overall Number of Participants Analyzed: 6	Results	7
Measure Type: Number	Results	8
Unit of Measure: participants  1	Results	9
Results 2:	Results	10
Arm/Group Title: Stratum 2: Had Not Received Hormonal Therapy	Results	11
Arm/Group Description: Participants had not received hormonal therapy	Results	12
Overall Number of Participants Analyzed: 5	Results	13
Measure Type: Number	Results	14
Unit of Measure: participants  0	Results	15
Adverse Events 1:	Adverse Events	0
Total: 1/6 (16.67%)	Adverse Events	1
Fever  [1]1/6 (16.67%)	Adverse Events	2
fever	HP:0001945	0-5
Adverse Events 2:	Adverse Events	3
Total: 0/5 (0.00%)	Adverse Events	4
Fever  [1]0/5 (0.00%)	Adverse Events	5
fever	HP:0001945	0-5
